Tagged with R

TEVA Germany The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process continued with the recent acquisition of AWD Pharma in 2008. What as the impact of such acquisitions in your German…

Anugerah Corporation The development of the Local Pharmaceutical industry companies has gone through rough times, competing from the very beginning with MNCs and going through the economic shock in the 90’s. In this period while many companies couldn’t cope with the market competition, Anguerah Corporation succeeded in positioning itself as one of…

Euticals group After a long experience at BMS, you are since 2002 at the head of Euticals- a well established group consisting of four entities (Euticals, Ambrosia, Prochisa and Pro.Bio.Sint), each of them developing and producing Active Pharmaceutical Ingredients (APIs) by different processes. To begin, could you give us an overview of…

Parexel International Italy Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and which opportunities does the local environment provide to the group? The high number of clinical trials conducted in Italy every…

AstraZeneca South Korea You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector from a Chinese perspective? My exposure to Korea while in China was much more on the drug discovery and development…

Bausch & Lomb Germany With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities that no other company could thanks to its own transformations and special needs. Since Bausch&Lomb changed ownership in 2007, our…

International Pharmaceutical Manufacturing Gr Although Indonesia in the last ten years had the second highest growth in ASIA in terms of drugs’ production and consumption, the market share of research based companies has dropped from 50% to 25%. What have been the main drivers leading to the current scenario? The share of international companies…

Neurotech Pharmaceuticals What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when special new laws were passed by the Korean government aiming to get professors to contribute to the development of the…

Astellas Pharma Germany Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…

GPFarmasi Local firms have assumed an increasing role in the Indonesian pharmaceutical market representing today more than 75% of the market share and being able to provide over 90% of the medicines required by the population. What have been the main drivers of this change? The Indonesian pharmaceutical industry started in…

Lundbeck South Korea What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started out as a small organization, working through our local partner Whanin. In October that same year we managed to launch…

Korea Health Industry Development Institute What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics, functional food and medical care. First role is developing the health system and policies. The next role is funding R&D…